Biotechnology Transfer & Commercialization Conference
|Event Date/Time: Oct 24, 2012||End Date/Time: Oct 26, 2012|
|Registration Date: Oct 25, 2012|
|Early Registration Date: Sep 24, 2012|
A gulf exists between early research and commercial drug development. What is considered adequately researched at an academic level is vastly different than what is required on a commercial level. A lack of funding limits the resources many universities are able to devote to advancing new therapies and such efforts are typically beyond their core academic missions. The next steps in drug advancements are both challenging and expensive including advanced clinical trials up to the marketing of successful therapies, requiring significant investments. An era of biotech business paradigm shifts requires a new understanding among the various market segments.
Bridging the gulf requires a dialogue among academic, investment and commercial organizations.
GTCâ€™s Biotechnology Transfer & Commercialization Conference will bring together the players needed to move the industry forward. Leading universities, pharmaceutical companies, venture capital, foundations and biotech companies will come together to share their perspectives, discuss new models of cooperation and develop the business relationships that get deals done and bring new therapies successfully to market.
Conference Advisory Board Members:
Patrick Enright, Managing Director, Longitude Capital
Turner Jenkins, Associate, Pappas Ventures
Joel Kirschbaum, Director, UCSF
David Lewin, Senior Associate Director of Licensing, Yale University
Jonathan Lourie, Partner, Edwards Wildman Palmer
Benjamin Martin, Member, Epstein Becker Green
Nina Kjellson, General Partner, InterWest
Christopher K. Mirabelli, HealthcareVentures
Dushyant Pathak, Associate Vice Chancellor, Office of Research, University of California, Davis
Ben Perkins, Group Head, US Life Sciences M&A, Ernst & Young
Keld Sorensen, Senior Manager, Siemens Healthcare Diagnostics
We look forward to seeing you at the conference!